Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Common Equity (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Common Equity data on record, last reported at $648.0 million in Q4 2025.

  • For Q4 2025, Common Equity rose 191.42% year-over-year to $648.0 million; the TTM value through Dec 2025 reached $648.0 million, up 191.42%, while the annual FY2025 figure was $648.0 million, 191.42% up from the prior year.
  • Common Equity reached $648.0 million in Q4 2025 per TGTX's latest filing, up from $607.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $648.0 million in Q4 2025 and bottomed at $27.4 million in Q1 2023.
  • Average Common Equity over 5 years is $237.5 million, with a median of $184.9 million recorded in 2024.
  • Peak YoY movement for Common Equity: soared 33010.94% in 2021, then tumbled 83.9% in 2023.
  • A 5-year view of Common Equity shows it stood at $237.2 million in 2021, then tumbled by 75.3% to $58.6 million in 2022, then surged by 173.95% to $160.5 million in 2023, then surged by 38.54% to $222.4 million in 2024, then soared by 191.42% to $648.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $648.0 million in Q4 2025, $607.2 million in Q3 2025, and $276.4 million in Q2 2025.